Benitec Biopharma (NASDAQ:BNTC) Given New $22.00 Price Target at Citizens Jmp

Benitec Biopharma (NASDAQ:BNTC) had its price target lifted by Citizens Jmp from $20.00 to $22.00 in a report released on Tuesday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.

Several other analysts also recently commented on BNTC. TD Cowen initiated coverage on shares of Benitec Biopharma in a report on Monday, July 7th. They set a “buy” rating for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $20.00 price objective on shares of Benitec Biopharma in a report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. Citigroup reaffirmed an “outperform” rating on shares of Benitec Biopharma in a report on Tuesday. Finally, Zacks Research downgraded shares of Benitec Biopharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.83.

Benitec Biopharma Stock Performance

Shares of BNTC stock opened at $15.71 on Tuesday. The company has a market capitalization of $412.39 million, a price-to-earnings ratio of -10.69 and a beta of 0.41. The company has a debt-to-equity ratio of 0.01, a quick ratio of 54.67 and a current ratio of 54.67. The company has a 50-day simple moving average of $14.48 and a 200 day simple moving average of $13.78. Benitec Biopharma has a 52 week low of $9.10 and a 52 week high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Thursday, September 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.18). On average, sell-side analysts predict that Benitec Biopharma will post -1.48 earnings per share for the current year.

Institutional Trading of Benitec Biopharma

Institutional investors have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey bought a new stake in Benitec Biopharma in the 2nd quarter valued at about $38,000. JPMorgan Chase & Co. acquired a new position in shares of Benitec Biopharma in the 2nd quarter valued at approximately $80,000. Bank of America Corp DE raised its position in shares of Benitec Biopharma by 2,255.8% in the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 6,587 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Benitec Biopharma in the 2nd quarter valued at approximately $93,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Benitec Biopharma in the 2nd quarter valued at approximately $95,000. Institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.